- Home
- ZNTL vs FINS Comparison
ZNTL vs FINS Comparison
Compare ZNTL & FINS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- FINS
- Stock Information
- Founded
- ZNTL 2014
- FINS 2019
- Country
- ZNTL United States
- FINS United States
- Employees
- ZNTL N/A
- FINS N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- FINS Finance/Investors Services
- Sector
- ZNTL Health Care
- FINS Finance
- Exchange
- ZNTL Nasdaq
- FINS Nasdaq
- Market Cap
- ZNTL 238.2M
- FINS 328.8M
- IPO Year
- ZNTL 2020
- FINS N/A
- Fundamental
- Price
- ZNTL $3.12
- FINS $13.18
- Analyst Decision
- ZNTL Buy
- FINS
- Analyst Count
- ZNTL 7
- FINS 0
- Target Price
- ZNTL $10.86
- FINS N/A
- AVG Volume (30 Days)
- ZNTL 1.2M
- FINS 78.0K
- Earning Date
- ZNTL 11-04-2024
- FINS 01-01-0001
- Dividend Yield
- ZNTL N/A
- FINS 9.97%
- EPS Growth
- ZNTL N/A
- FINS N/A
- EPS
- ZNTL N/A
- FINS N/A
- Revenue
- ZNTL $40,560,000.00
- FINS N/A
- Revenue This Year
- ZNTL N/A
- FINS N/A
- Revenue Next Year
- ZNTL N/A
- FINS N/A
- P/E Ratio
- ZNTL N/A
- FINS N/A
- Revenue Growth
- ZNTL N/A
- FINS N/A
- 52 Week Low
- ZNTL $2.83
- FINS $11.61
- 52 Week High
- ZNTL $18.24
- FINS $12.57
- Technical
- Relative Strength Index (RSI)
- ZNTL 44.34
- FINS 53.08
- Support Level
- ZNTL $2.92
- FINS $13.02
- Resistance Level
- ZNTL $3.23
- FINS $13.18
- Average True Range (ATR)
- ZNTL 0.17
- FINS 0.14
- MACD
- ZNTL 0.00
- FINS -0.02
- Stochastic Oscillator
- ZNTL 38.33
- FINS 82.26
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
About FINS Angel Oak Financial Strategies Income Term Trust of Beneficial Interest
Angel Oak Financial Strats Income Term is a non-diversified, closed-end management investment company. The fund's objective is to seek current income with a secondary objective of total return. In pursuing its investment objective, the fund invests mainly in debt issued by financial institutions, including subordinated debt, unrated debt, senior debt, and high-yield securities.